The Caviar Cruise investment strategy represents a systematic method for finding good companies suitable for long-term investment. This approach concentrates on businesses showing steady revenue and profit increases, high returns on capital used, acceptable debt amounts, and good profit quality. By using these number-based filters, investors can search for companies with lasting competitive edges and maintainable business structures that might provide increasing returns over many years.
Danaher Corp (NYSE:DHR) appears as a strong candidate via this filtering process, satisfying several conditions that quality investors usually look for. The company's varied activities in biotechnology, life sciences, and diagnostics place it in increasing healthcare and scientific fields, giving it access to long-term trends in medical study and healthcare development.
Financial Performance Measurements
Danaher's past performance matches the Caviar Cruise method's focus on steady increase and operational quality:
-
Revenue Increase: The company has reached a 5.81% compound annual growth rate over the last five years, going above the screen's 5% minimum level. This shows the company's capacity to steadily make its business operations larger.
-
EBIT Increase: With a 9.77% five-year CAGR in EBIT increase, Danaher not only goes beyond the 5% need but also goes past its revenue increase. This shows better operational effectiveness and possible price-setting ability, as the Caviar Cruise strategy specifically looks for companies where profit increase is faster than revenue increase.
-
Return on Invested Capital: Danaher's ROIC without cash, goodwill, and intangibles is at a notable 36.01%, more than two times the screen's 15% need. This outstanding return shows the company's ability to effectively use capital and create large profits from its investments.
Financial Condition and Quality Signs
The company's financial setup and profit quality further back its fit for quality-focused investors:
-
Debt Handling: Danaher's debt-to-free-cash-flow measurement of 3.36 years fits well within the screen's acceptable span of 0-5 years. This shows the company could in theory pay back all its debt in under three and a half years using present free cash flow.
-
Profit Quality: The company's five-year average profit quality of 125.69% is much higher than the 75% limit. This measurement, which matches free cash flow to net income, indicates Danaher turns accounting profits into real cash more effectively than needed, pointing to high-grade earnings.
Fundamental Analysis Summary
According to Chartmill's detailed fundamental analysis report, Danaher gets a 5 out of 10 total when measured against industry counterparts in the Life Sciences Tools & Services field. The study shows several important positives and points to think about:
The company shows very good profitability with solid margins that are some of the best in the industry. Its operating margin of 19.48% does better than 84% of industry rivals, while profit margins of 14.43% are higher than 82% of peers. However, the report mentions some worries about financial condition, especially the connection between return on invested capital and capital cost.
From a price perspective, Danaher trades at a P/E ratio of 27.23, about the same as the S&P 500 average but less expensive than 75% of industry rivals. Increase measurements show stable past performance with analysts predicting continued earnings growth of about 9.65% each year.
Investment Points
While Danaher meets many number-based conditions for quality investing, potential investors should think about several non-number factors. The company works in structurally increasing markets pushed by continuing scientific study and healthcare progress. Its varied collection across biotechnology, life sciences, and diagnostics supplies several increase sources and lowers reliance on any one market area.
The company's business structure, focusing on necessary scientific tools and supplies, shows signs of price-setting ability and repeating income flows. However, investors should do their own evaluation of management skill, competitive edges, and business strength during economic declines.
For investors wanting to find more companies that meet the Caviar Cruise conditions, the full filtering results give a beginning place for more study.
Disclaimer: This analysis is for information only and does not make up investment guidance, suggestion, or backing of any security. Investors should do their own study and talk with financial advisors before making investment choices. Past performance does not ensure future outcomes.
